Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C9H14N4O2 |
| Molecular Weight | 210.2331 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN1C=NC(C(=O)NC)=C1C(=O)NC
InChI
InChIKey=RYRFAMRQBZNEPX-UHFFFAOYSA-N
InChI=1S/C9H14N4O2/c1-4-13-5-12-6(8(14)10-2)7(13)9(15)11-3/h5H,4H2,1-3H3,(H,10,14)(H,11,15)
| Molecular Formula | C9H14N4O2 |
| Molecular Weight | 210.2331 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Etimizol was developed at the Institute of Experimental Medicine, St.Petersburg USSR in 1960s. Ethymisole, or 4,5-di(N-methylcarbamoyl)-1-ethyl-imidazole, is a cognitive enhancer and nootropic drug, the molecular target of which is a multifunctional protein kinase C K2 (casein kinase II). Etimizol improves short-term memory, strengthens adrenocorticotropic function of a hypophysis; excites respiratory center.
It is indicated for the prevention of respiratory depression of various etiology, also etimizol is used for the treatment of astheno-depressive syndrome, arthritis, chronic obstructive pulmonary disease and bronchial asthma. Etimizol is marketed exclusively in Russia.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL3832943: Casein kinase 2 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Preventing | Etimizol Approved UseEtimizol is indicated for the prevention of respiratory depression of various etiology, also etimizol is used for the treatment of astheno-depressive syndrome, arthritis, chronic obstructive pulmonary disease and bronchial asthma. |
|||
| Primary | Etimizol Approved UseEtimizol is indicated for the prevention of respiratory depression of various etiology, also etimizol is used for the treatment of astheno-depressive syndrome, arthritis, chronic obstructive pulmonary disease and bronchial asthma. |
|||
| Primary | Etimizol Approved UseEtimizol is indicated for the prevention of respiratory depression of various etiology, also etimizol is used for the treatment of astheno-depressive syndrome, arthritis, chronic obstructive pulmonary disease and bronchial asthma. |
|||
| Primary | Etimizol Approved UseEtimizol is indicated for the prevention of respiratory depression of various etiology, also etimizol is used for the treatment of astheno-depressive syndrome, arthritis, chronic obstructive pulmonary disease and bronchial asthma. |
|||
| Primary | Etimizol Approved UseEtimizol is indicated for the prevention of respiratory depression of various etiology, also etimizol is used for the treatment of astheno-depressive syndrome, arthritis, chronic obstructive pulmonary disease and bronchial asthma. |
PubMed
| Title | Date | PubMed |
|---|---|---|
| [Isolation and study of cAMP-independent chromatin protein kinases from brain cells]. | 1991 Jan |
|
| [Phosphorylation of HMG proteins during change in the chromatin transcription activity of neuronal and glial nuclei of the rat brain]. | 1993 Jul |
|
| Protein kinase CK2 and regulation of Ca2+-ATPase activity in brain neuron chromatin in rats during aging. | 2002 Jun |
|
| [Ethymisole: reassessing and old drug]. | 2007 May-Jun |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://infomeds.net/etimizol.html
Orally 0,05 - 0,1 g 3 times a day after food; intravenously on 1 - 2 ml of 1,5% of solution (slowly!), intramuscularly and subcutaneously on 4 - 5 ml of 1,5% of solution. A course of treatment at mental diseases 3 - 5 weeks.
Route of Administration:
Other
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 19:41:54 GMT 2023
by
admin
on
Fri Dec 15 19:41:54 GMT 2023
|
| Record UNII |
NG2MF3646P
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID30213984
Created by
admin on Fri Dec 15 19:41:54 GMT 2023 , Edited by admin on Fri Dec 15 19:41:54 GMT 2023
|
PRIMARY | |||
|
64-99-3
Created by
admin on Fri Dec 15 19:41:54 GMT 2023 , Edited by admin on Fri Dec 15 19:41:54 GMT 2023
|
PRIMARY | |||
|
NG2MF3646P
Created by
admin on Fri Dec 15 19:41:54 GMT 2023 , Edited by admin on Fri Dec 15 19:41:54 GMT 2023
|
PRIMARY | |||
|
6168
Created by
admin on Fri Dec 15 19:41:54 GMT 2023 , Edited by admin on Fri Dec 15 19:41:54 GMT 2023
|
PRIMARY |